Epoprostenol Sodium | CAS# 61849-14-7 | Potent Vasodilator

MedKoo Cat#: 317779 | Name: Epoprostenol Sodium

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Epoprostenol Sodium is a potent vasodilator and antiplatelet substance with a very short physiologic half-life. The sodium salt is used primarily for the treatment of pulmonary hypertension. Epoprostenol sodium inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue.

Chemical Structure

Epoprostenol Sodium

CAS# 61849-14-7

Theoretical Analysis

MedKoo Cat#: 317779

Name: Epoprostenol Sodium

CAS#: 61849-14-7

Chemical Formula: C20H31NaO5

Exact Mass: 0.0000

Molecular Weight: 374.45

Elemental Analysis: C, 64.15; H, 8.34; Na, 6.14; O, 21.36

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 400.00	2 Weeks
5mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Epoprostenol Sodium; Flolan; Prostaglandin I2; Prostacyclin; PGI2; PGX; Prostacyclin; Prostaglandin I(2); PGI2;

IUPAC/Chemical Name

sodium;(5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoate

InChi Key

LMHIPJMTZHDKEW-XQYLJSSYSA-M

InChi Code

InChI=1S/C20H32O5.Na/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22;/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24);/q;+1/p-1/b11-10+,15-8-;/t14-,16+,17+,18+,19-;/m0./s1

SMILES Code

CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)[O-])/O2)O)O.[Na+]

Appearance

Solid powder

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Certificate of Analysis

View CoA: current batch, Lot#C21M11C02

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 374.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Saito Y, Nakamura K, Akagi S, Sarashina T, Ejiri K, Miura A, Ogawa A, Matsubara H, Ito H. Epoprostenol sodium for treatment of pulmonary arterial hypertension. Vasc Health Risk Manag. 2015 May 14;11:265-70. doi: 10.2147/VHRM.S50368. PMID: 25999730; PMCID: PMC4437604. 2: Kiernan FJ, Kluger J, Regnier JC, Rutkowski M, Fieldman A. Epoprostenol sodium (prostacyclin) infusion in acute myocardial infarction. Br Heart J. 1986 Nov;56(5):428-32. doi: 10.1136/hrt.56.5.428. PMID: 3539163; PMCID: PMC1236888. 3: Bandilla D, Goverde M, Giudici P, Lambert O. Microbial challenge test of a novel epoprostenol sodium formulation. Drug Des Devel Ther. 2017 Aug 10;11:2347-2357. doi: 10.2147/DDDT.S140033. PMID: 28848328; PMCID: PMC5557400. 4: Vane JR. Prostacyclin. J R Soc Med. 1983 Apr;76(4):245-9. doi: 10.1177/014107688307600401. PMID: 6341583; PMCID: PMC1438970. 5: Chin KM, Badesch DB, Robbins IM, Tapson VF, Palevsky HI, Kim NH, Kawut SM, Frost A, Benton WW, Lemarie JC, Bodin F, Rubin LJ, McLaughlin V. Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. Am Heart J. 2014 Feb;167(2):218-225.e1. doi: 10.1016/j.ahj.2013.08.008. Epub 2013 Oct 16. PMID: 24439983. 6: Nickolson RC, Town MH, Vorbrüggen H. Prostacyclin-analogs. Med Res Rev. 1985 Jan-Mar;5(1):1-53. doi: 10.1002/med.2610050102. PMID: 3884930. 7: Tamura Y, Ono T, Fukuda K, Satoh T, Sasayama S. Evaluation of a new formulation of epoprostenol sodium in Japanese patients with pulmonary arterial hypertension (EPITOME4). Adv Ther. 2013 May;30(5):459-71. doi: 10.1007/s12325-013-0029-0. Epub 2013 May 8. Erratum in: Adv Ther. 2013 May;30(5):554-5. PMID: 23653230; PMCID: PMC3680653. 8: Jacobs W, Vonk-Noordegraaf A. Epoprostenol in pulmonary arterial hypertension. Expert Opin Drug Metab Toxicol. 2009 Jan;5(1):83-90. doi: 10.1517/17425250802622962. PMID: 19236231. 9: Nicolas LB, Gutierrez MM, Dingemanse J. Comparative pharmacokinetic, pharmacodynamic, safety, and tolerability profiles of 3 different formulations of epoprostenol sodium for injection in healthy men. Clin Ther. 2013 Apr;35(4):440-9. doi: 10.1016/j.clinthera.2013.02.013. Epub 2013 Mar 15. PMID: 23498778. 10: Lambert O, Bandilla D, Iyer R, Witchey-Lakshmanan L, Palepu N. Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted. Drug Des Devel Ther. 2012;6:61-70. doi: 10.2147/DDDT.S29916. Epub 2012 Mar 28. PMID: 22563237; PMCID: PMC3340107. 11: del Castillo Palma MJ, García Hernández FJ, Sánchez Román J. Epoprostenol and thyroid disease. Endocr Pract. 2010 Jan-Feb;16(1):133; author reply 133-4. doi: 10.4158/EP.16.1.130. PMID: 20180281. 12: Caruana RJ, Smith MC, Clyne D, Crow JW, Zinn JM, Diehl JH. Controlled study of heparin versus epoprostenol sodium (prostacyclin) as the sole anticoagulant for chronic hemodialysis. Blood Purif. 1991;9(5-6):296-304. doi: 10.1159/000170027. PMID: 1819317. 13: Lambert O, Bandilla D. Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension. Drug Des Devel Ther. 2012;6:235-44. doi: 10.2147/DDDT.S31628. Epub 2012 Sep 17. PMID: 23049244; PMCID: PMC3459691. 14: Hesselgrave B. Pulmonary hypertension update. Case Manager. 2005 Nov- Dec;16(6):61-6; quiz 67. doi: 10.1016/j.casemgr.2005.09.005. PMID: 16326325. 15: Chattaraj SC. Treprostinil sodium Pharmacia. Curr Opin Investig Drugs. 2002 Apr;3(4):582-6. PMID: 12090728. 16: Haywood GA, Adams KF Jr, Gheorghiade M, McKenna WJ. Is there a role for epoprostenol in the management of heart failure? Am J Cardiol. 1995 Jan 19;75(3):44A-50A. doi: 10.1016/s0002-9149(99)80382-8. PMID: 7840054. 17: Wagner BM. Prostacyclin and atherosclerosis. Hum Pathol. 1985 Mar;16(3):201. doi: 10.1016/s0046-8177(85)80001-0. PMID: 3882549. 18: Ferrantino M, White RJ. Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother. 2011 Nov;12(16):2583-93. doi: 10.1517/14656566.2011.622269. PMID: 21988216. 19: Kawabe M, Hagiwara A, Yoshino H, Miyashita K, Nakanishi T, Sano M, Tamano S, Okamoto K, Miura K, Tokado H. Epoprostenol sodium, a prostaglandin I2, lacks tumor promoting effects in a medium-term liver carcinogenesis bioassay in rats. Cancer Lett. 2001 Jan 26;162(2):141-7. doi: 10.1016/s0304-3835(00)00632-7. PMID: 11146218. 20: Sugawara A, Kudo M, Saito A, Matsuda K, Uruno A, Ito S. Novel effects of beraprost sodium on vasculatures. Int Angiol. 2010 Apr;29(2 Suppl):28-32. PMID: 20357746.